2. Search Result
Search Result
Results for "

diastolic

" in MedChemExpress (MCE) Product Catalog:

44

Inhibitors & Agonists

5

Peptides

7

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-103193
    NKH477

    Colforsin dapropate hydrochloride

    		 Adenylate Cyclase Cardiovascular Disease
    NKH477 (Colforsin dapropate hydrochloride) directly activates the catalytic unit of adenylate cyclase and increases intracellular cAMP. NKH477 is a forskolin derivative that improves cardiac failure mainly through its beneficial effects on diastolic cardiac function. NKH477 exerts an antiproliferative effect in vivo with an altered cytokine profile to inhibit the acute rejection of rat orthotopic lung allografts .
    NKH477
  • HY-114252
    Strophanthidin
    1 Publications Verification

    		 Na+/K+ ATPase Cardiovascular Disease
    Strophanthidin is a naturally available cardiac glycoside . Strophanthidin 0.1 and 1 nmol/L increases and 1~100 μmol/L inhibits the Na+/K+-ATPase activities, but Strophanthidin 10 and 100 nmol/L does not affect Na+/K+-ATPase activities in cardiac sarcolemmal . Strophanthidin increases both diastolic and systolic intracellular Ca 2+ concentration .
    Strophanthidin
  • HY-B2209
    Hydroxocobalamin
    3 Publications Verification

    Vitamin B12a

    		 Endogenous Metabolite Neurological Disease Metabolic Disease
    Hydroxocobalamin (Vitamin B12a) is a cyanide antidote. Hydroxocobalamin can decrease the cell and plasma cyanide concentrations and increase survival rate in acute cyanide poisoning. Hydroxocobalamin can improve newborn Cbl-C defect-induced metabolic profile and neurocognitive outcome. Hydroxocobalamin can normalize Vitamin B12 deficiency. Hydroxocobalamin can induce acute kidney injury. Hydroxocobalamin can be used for the researches of metabolic and neurological disease .
    Hydroxocobalamin
  • HY-103175
    PSB36
    1 Publications Verification

    		 Adenosine Receptor Cardiovascular Disease Neurological Disease Inflammation/Immunology
    PSB36 is a highly selective A1 adenosine receptor antagonist, with a Ki of 0.12 nM and a Kd of 0.7 nM. Systemic administration of PSB36 reduces formalin- and Carrageenan (HY-125474)-induced edema in mice and decreases pain-related behaviors, with no local paw activity. PSB36 prolongs the APD90 of rat and human atria, produces a frequency-dependent prolongation of rat atrial ERP, increases the diastolic threshold of rat atria, and shortens the duration of atrial fibrillation episodes. PSB36 can be used in research related to inflammatory pain, inflammatory hyperalgesia, edema and atrial fibrillation .
    PSB36
  • HY-W005255
    3-(3-Hydroxyphenyl)propionic acid

    		Endogenous Metabolite Cardiovascular Disease
    3-(3-Hydroxyphenyl)propionic acid (3HPPA) is an endothelium-dependent nitric oxide (NO) release promoter and endothelial nitric oxide synthase (eNOS) activator. 3-(3-Hydroxyphenyl)propionic acid activates eNOS to mediate vascular smooth muscle relaxation and enhances endothelial cell NO synthesis, inducing vasodilation and reducing peripheral vascular resistance. 3-(3-Hydroxyphenyl)propionic acid can dose-dependently reduce systolic and diastolic blood pressure in spontaneously hypertensive rats (SHR) without affecting cardiac contractility or heart rate. 3-(3-Hydroxyphenyl)propionic acid has antihypertensive and vascular protective effects and can be used in the prevention and treatment of cardiovascular diseases .
    3-(3-Hydroxyphenyl)propionic acid
  • HY-18282
    AZ876

    		LXR Cardiovascular Disease Metabolic Disease Cancer
    AZ876 is a selective, orally active agonist of liver X receptor (LXRα/β) (Ki=0.007 μM [LXRα, human], 0.011 μM [LXRβ, human]. AZ876 induces the expression of target genes such as ABCA1 and ABCG1, promotes reverse cholesterol transport (RCT) and regulates lipid metabolism and anti-inflammatory effects. AZ876 increases cardiac polyunsaturated fatty acid levels, reduces myocardial fibrosis, and reduces lesion area and monocyte adhesion in atherosclerosis models. AZ876 can be used in cardiovascular disease research, such as preventing and treating β-adrenergic-induced cardiac diastolic dysfunction and inhibiting the progression of atherosclerosis .
    AZ876
  • HY-118060
    Dipeptide 2

    N-Valyltryptophan; Val-Trp

    		 Angiotensin-converting Enzyme (ACE) Calcium Channel NO Synthase Cardiovascular Disease
    Dipeptide 2 (N-Valyltryptophan) is an orally active, competitive angiotensin-converting enzyme (ACE) inhibitory peptide with an IC50 of 10.50 μM. Dipeptide 2 reduces intracellular Calcium ions. Dipeptide 2 significantly increases the content of NO, inhibits the production of ET-1, and induces the phosphorylation of eNOS. Dipeptide 2 decreases the systolic and diastolic blood pressure of spontaneously hypertensive rats .
    Dipeptide 2
  • HY-106844A
    (+)-EMD 57033

    		Phosphodiesterase (PDE) Cardiovascular Disease
    (+)-EMD 57033 is a cardiac troponin C (cTnC) activator, is a dominant Ca 2+ sensitizer. (+)-EMD 57033 binds the cardiac/slow skeletal troponin C isoform and exerts myocardial contractile promotion function .
    (+)-EMD 57033
  • HY-148804
    Vemtoberant

    APD418

    		 Adrenergic Receptor Cardiovascular Disease
    Vemtoberant is a β3-adrenergic receptor inhibitor with a human Ki of 8.2 nM, and exhibits 400- to 600-fold selectivity over human β1-AR and β2-AR. Vemtoberant attenuates β3-AR-mediated cardiac inhibition. Vemtoberant can be used for the research of systolic heart failure .
    Vemtoberant
  • HY-P3304
    MR 409

    		GHSR Neurological Disease Cancer
    MR 409 is a selected growth hormone-releasing hormone (GHRH) agonist. MR 409 has remarkable neuroprotective effects through enhancing endogenous neurogenesis in cerebral ischemic mice. MR 409 also inhibits the in vivo growth of lung cancer .
    MR 409
  • HY-161119
    Drpitor1a

    		Dynamin Reactive Oxygen Species (ROS) Cardiovascular Disease Cancer
    Drpitor1a is a potent Drp1 inhibitor. Drpitor1a inhibits mitochondrial ROS production, preventes mitochondrial fission, and improves right ventricular diastolic dysfunction during IR (ischemia reperfusion) injury. Drpitor1a has the potential for the research of lung cancer [1]
    Drpitor1a
  • HY-19870C
    Setmelanotide monoacetate
    5+ Cited Publications

    RM-493 monoacetate; BIM-22493 monoacetate; IRC-022493 monoacetate

    		 Melanocortin Receptor Calmodulin AMPK Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    Setmelanotide monoacetate (RM-493 monoacetate) is a blood-brain barrier-permeable, selective MC4R agonist with a Ki value of 2.1 nM for hMC4R. Setmelanotide monoacetate activates the CaMKK2/AMPK signaling pathway. Setmelanotide monoacetate mediates body weight homeostasis, feeding regulation and energy expenditure modulation; it reduces food intake, induces weight loss, decreases obesity severity, increases daytime activity and energy expenditure, lowers levels of leptin, triglycerides, fasting insulin and diastolic blood pressure, improves insulin sensitivity, glucose tolerance and fatty liver condition, and reverses respiratory depression. Setmelanotide monoacetate is applicable to research related to obesity, hyperinsulinemia, fatty liver and respiratory depression .
    Setmelanotide monoacetate
  • HY-N7491A
    Ent-(+)-Verticilide

    		Calcium Channel Cancer
    ent-(+)-verticilide is a potent and selective inhibitor of cardiac ryanodine receptor (RyR2) calcium release channels with antiarrhythmic activity. ent-(+)-verticilide inhibits RyR2-mediated diastolic Ca2+ leak and exhibits higher potency and a distinct mechanism of action compared with theDantrolene and Tetracaine. ent-(+)-verticilide is a useful tool to investigate the therapeutic potential of targeting RyR2 hyperactivity in heart and brain pathologies .
    Ent-(+)-Verticilide
  • HY-124873
    SERCA2a activator 1

    		Calcium Channel Cardiovascular Disease
    SERCA2a activator 1 (Compound A) is a sarco/endoplasmic reticulum Ca 2+-dependent ATPase 2a (SERCA2a) activator. SERCA2a activator 1 attenuates phospholamban inhibition and enhances the systolic and diastolic functions of the heart. SERCA2a activator 1 can be used for heart failure .
    SERCA2a activator 1
  • HY-P10336
    Serpinin

    		Serpin Neurological Disease Endocrinology
    Serpinin is an agonist of the protease inhibitor Nexin-1 (PN-1). Serpinin upregulates the expression of PN-1 through the cAMP-PKA-Sp1 signaling pathway, promoting granule biogenesis in endocrine cells. Serpinin is used in research related to the regulation of secretory function . Serpinin is a selective agonist for β-adrenergic receptors. Serpinin interacts with β1-adrenergic receptors to activate the AC-cAMP-PKA pathway, which regulates myocardial systolic and diastolic function. pGlu-serpinin upregulates Bcl2 mRNA transcription and exerts neuroprotective effects .
    Serpinin
  • HY-172424
    Delocamten

    		Myosin Cardiovascular Disease
    Delocamten is the inhibitor for cardiac myosin with an IC50 of 1.1 μM. Delocamten can be used in researchs of hypertrophic cardiomyopathy, left ventricular hypertrophy and diastolic dysfunction .
    Delocamten
  • HY-123268A
    Ro 363 hydrochloride

    		Adrenergic Receptor Cardiovascular Disease
    Ro 363 hydrochloride, an effective inotropic stimulant, is a potent and highly selective β1-adrenoceptor agonist. Ro 363 hydrochloride is a cardiovascular modulator that reduces diastolic blood pressure and pronounces increases in myocardial contractility .
    Ro 363 hydrochloride
  • HY-123268
    Ro 363

    		Adrenergic Receptor Cardiovascular Disease
    Ro 363, an effective inotropic stimulant, is a potent and highly selective β1-adrenoceptor agonist. RO 363 is a cardiovascular modulator that reduces diastolic blood pressure and pronounces increases in myocardial contractility .
    Ro 363
  • HY-N3931
    Gardneramine

    		Others Cardiovascular Disease
    Gardneramine is an orally active alkaloid that acts like papaverine. Gardneramine has peripheral vascular diastolic effect, direct inhibition on myocardium and central inhibition. Gardneramine showed antihypertensive, vasodilatation and atrial inhibition effects in rabbit, dog and guinea pig models, respectively. Gardneramine also inhibits the movement of smooth muscle organs such as the stomach and intestines .
    Gardneramine
  • HY-122215
    Tilisolol hydrochloride

    N-696

    		 Adrenergic Receptor Endocrinology
    Tilisolol hydrochloride (N-696) is a non-selective β-adrenergic antagonist with vasodilatory and hypotensive activities. Tilisolol hydrochloride exerts its effects in canine coronary arteries by opening ATP-sensitive K+ channels. Tilisolol hydrochloride exhibits concentration-dependent relaxation in KCl-precontracted rat thoracic aorta. Tilisolol hydrochloride reduces diastolic blood pressure in a dose-dependent manner and slightly increases heart rate in spinal cord stimulated rats .
    Tilisolol hydrochloride
  • HY-Z7733
    O-Desmethylcarvedilol

    Desmethylcarvedilol; BM-14242

    		 Calcium Channel Metabolic Disease
    O-Desmethylcarvedilol (Desmethylcarvedilol) is an active metabolite of the non-selective β-adrenergic receptor (β-AR) antagonist Carvedilol (HY-B0006). O-Desmethylcarvedilol inhibits store-overload-induced calcium release in HEK293 cells expressing the ryanodine receptor 2 (RyR2) R4496C (RyR2 R4496C) mutation (IC50 = 7.62 µM). O-Desmethylcarvedilol reduces increases in heart rate and prevents decreases in diastolic blood pressure induced by Isoproterenol (HY-B0468) in conscious rabbits (ED50s = 32 and 5 µg/kg, respectively) .
    O-Desmethylcarvedilol
  • HY-164631
    EL20

    		Calcium Channel Cardiovascular Disease
    EL20 is a selective cardiac ryanodine receptor 2 (RyR2) inhibitor. EL20 inhibits diastolic Ca 2+ leakage from the sarcoplasmic reticulum, reducing delayed afterdepolarizations and triggered arrhythmias. EL20 is promising for research of cardiovascular diseases .
    EL20
  • HY-105362
    PD 155080

    		Endothelin Receptor Cardiovascular Disease
    PD 155080 is a selective endothelin A receptor (ETA receptor) antagonist. PD 155080 reduces coronary resistance in the isolated rat heart model. PD 155080 improves myocardial systolic function and diastolic function in the ischemia/reperfusion model. PD 155080 can be used for the study of cardiovascular diseases .
    PD 155080
  • HY-161608
    Myosin modulator 1

    		Myosin Cardiovascular Disease
    Myosin modulator 1 (Compound B141) is a modulator for myosin, that inhibits ATPase in rabbits psoas, porcine atria and in porcine ventricle, with IC25s of 0.42, 0.13 and 3.09 μM, respectively. Myosin modulator 1 regulates systolic cardiac performance in Sprague Dawley rats .
    Myosin modulator 1
  • HY-161609
    Myosin modulator 2

    		Myosin Cardiovascular Disease
    Myosin modulator 2 (Compound B172) is a modulator for myosin, that inhibits ATPase in rabbits psoas, porcine atria and in porcine ventricle, with IC25s of 2.013, 2.94 and 20.93 μM, respectively. Myosin modulator 2 regulates systolic cardiac performance in Sprague Dawley rats .
    Myosin modulator 2
  • HY-18282R
    AZ876 (Standard)

    		LXR Cardiovascular Disease Metabolic Disease Cancer
    AZ876 (Standard) is the analytical standard of AZ876. This product is intended for research and analytical applications. AZ876 is a selective, orally active agonist of liver X receptor (LXRα/β) (Ki=0.007 μM [LXRα, human], 0.011 μM [LXRβ, human]. AZ876 induces the expression of target genes such as ABCA1 and ABCG1, promotes reverse cholesterol transport (RCT) and regulates lipid metabolism and anti-inflammatory effects. AZ876 increases cardiac polyunsaturated fatty acid levels, reduces myocardial fibrosis, and reduces lesion area and monocyte adhesion in atherosclerosis models. AZ876 can be used in cardiovascular disease research, such as preventing and treating β-adrenergic-induced cardiac diastolic dysfunction and inhibiting the progression of atherosclerosis .
    AZ876 (Standard)
  • HY-W416440
    Esmolol acid hydrochloride

    ASL-8123 hydrochloride

    		 Adrenergic Receptor Cardiovascular Disease Metabolic Disease
    Esmolol acid (ASL-8123) hydrochloride is a weak β-adrenergic receptor antagonist. Esmolol acid hydrochloride inhibits the heart rate and diastolic blood pressure response induced by Isoproterenol (HY-B0468) in a dose-dependent manner and can be used in studies of renal failure .
    Esmolol acid hydrochloride
  • HY-106688A
    Alinidine hydrobromide

    St-567 hydrobromide

    		 Potassium Channel Cardiovascular Disease
    Alinidine (St-567) hydrobromide is a specific bradycardic agent. Alinidine hydrobromide reduces the slope of the diastolic depolarization in sinoatrial tissue and Purkinje fibers. Alinidine hydrobromide shows antiischemic and antiarrhythmic effects .
    Alinidine hydrobromide
  • HY-114252R
    Strophanthidin (Standard)

    		Reference Standards Na+/K+ ATPase Cardiovascular Disease
    Strophanthidin (Standard) is the analytical standard of Strophanthidin. This product is intended for research and analytical applications. Strophanthidin is a naturally available cardiac glycoside . Strophanthidin 0.1 and 1 nmol/L increases and 1~100 μmol/L inhibits the Na+/K+-ATPase activities, but Strophanthidin 10 and 100 nmol/L does not affect Na+/K+-ATPase activities in cardiac sarcolemmal . Strophanthidin increases both diastolic and systolic intracellular Ca2+ concentration .
    Strophanthidin (Standard)
  • HY-N1115
    Tubotaiwine

    (+)-Tubotaiwine; NSC 306222; Tubotaiwin

    		 Others Cardiovascular Disease
    Tubotaiwine ((+)-Tubotaiwine), an alkaloid, has beneficial effect on cadmium (Cd) induced hypertension in rats. Tubotaiwine regulates systolic, diastolic and mean arterial blood pressure of the Cd exposed rats. Tubotaiwine reduces arterial stiffness, inhibits of oxidative stress and increases vascular remodeling .
    Tubotaiwine
  • HY-106024A
    Alagebrium bromide

    ALT711 bromide

    		 DNA Alkylator/Crosslinker Cardiovascular Disease
    Alagebrium bromide is an analog of Alagebrium Chloride (HY-106024B), a glucose cross-link blocker. Alagebrium Chloride disrupts glucose cross-links and may improve ventricular and arterial compliance. Alagebrium Chloride improves left ventricular diastolic filling and has the potential to inhibit diastolic heart failure (DHF).
    Alagebrium bromide
  • HY-106682
    Falipamil

    AQ-A 39

    		 Calcium Channel Cardiovascular Disease
    Falipamil (AQ-A 39), a calcium channel blocker, is a bradycardic agent. The bradycardic effect results from a reduction in the diastolic depolarization rate and a prolongation of the action potential duration .
    Falipamil
  • HY-129782
    SC-55858

    		SOD Cardiovascular Disease
    SC-55858 is an effective superoxide dismutase simulator. SC-55858 increased heart rate and decreased mean arterial pressure and left ventricular systolic and end-diastolic pressures in conscious dogs .
    SC-55858
  • HY-129706
    LY127210 free base

    		Others Cardiovascular Disease
    LY127210 (free base) is a potent vasodilator with antihypertensive effects that reduces pressure in chloralose-anesthetized spontaneously hypertensive rats primarily by direct arteriolar dilation and to a lesser extent by decreasing cardiac output. LY127210 (free base) reduces blood pressure, heart rate and left ventricular end-diastolic pressure in hypertensive rats by reducing vascular resistance .
    LY127210 free base
  • HY-101390B
    Niguldipine

    		Calcium Channel Cardiovascular Disease
    Niguldipine is a calcium channel blocker with activity in regulating cardiovascular function. Niguldipine can reduce systolic and diastolic blood pressure, thereby increasing heart rate and cardiac output. Niguldipine exhibits dose-dependent and sustained increases in coronary blood flow. Niguldipine also increases perfusion in the kidneys and femoral arteries, but the effect is temporary and to a lesser extent. The effect of Niguldipine on myocardial metabolism is not significant .
    Niguldipine
  • HY-N7164
    3-Oxo-24,25,26,27-tetranortirucall-7-ene-23(21)-lactone

    		Others Others
    3-Oxo-24,25,26,27-tetranortirucall-7-ene-23(21)-lactone is a tetranortirucallane-type triterpenoid that can be isolated from Dysoxylum lenticellatum. 3-Oxo-24,25,26,27-tetranortirucall-7-ene-23(21)-lactone has vasodilative effect with diastolic degree of 43.5% at 10 μg/mL .
    3-Oxo-24,25,26,27-tetranortirucall-7-ene-23(21)-lactone
  • HY-166478S
    O-Desmethyl carvedilol-d5

    Desmethylcarvedilol-d5; BM-14242-d5

    		 Isotope-Labeled Compounds Calcium Channel Metabolic Disease
    O-Desmethyl carvedilol-d5 (Desmethylcarvedilol-d5) is deuterium labeled O-Desmethylcarvedilol. O-Desmethylcarvedilol (Desmethylcarvedilol) is an active metabolite of the non-selective β-adrenergic receptor (β-AR) antagonist Carvedilol (HY-B0006). O-Desmethylcarvedilol inhibits store-overload-induced calcium release in HEK293 cells expressing the ryanodine receptor 2 (RyR2) R4496C (RyR2 R4496C) mutation (IC50 = 7.62 μM). O-Desmethylcarvedilol reduces increases in heart rate and prevents decreases in diastolic blood pressure induced by Isoproterenol (HY-B0468) in conscious rabbits (ED50s = 32 and 5 μg/kg, respectively) .
    O-Desmethyl carvedilol-d5
  • HY-P5762A
    Phoenixin-14 TFA

    PNX-14 TFA

    		 Orphan GPCR Glutathione Peroxidase Ferroptosis ERK Toll-like Receptor (TLR) Sirtuin FOXO Akt PKA MyD88 Reactive Oxygen Species (ROS) Apoptosis NF-κB Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
    Phoenixin-14 (PNX-14) TFA is an endogenous neuropeptide with multiple biological activities, and serves as the endogenous ligand of GPR173. Phoenixin-14 TFA reduces ROS production by inhibiting the HMGB1/TLR4/MyD88/NF-κB signaling axis, thereby exerting antioxidant and mitochondrial protective effects. Phoenixin-14 TFA inhibits FOXO3 phosphorylation by upregulating SIRT3 expression, suppresses apoptosis, and improves myocardial systolic/diastolic function. Phoenixin-14 TFA resists ferroptosis by activating the ATF4/SLC7A11/GPX4 axis; it activates ERK1/2 phosphorylation via GPR173. Phoenixin-14 TFA can be used in researches on neuroprotection, diabetes, cardiomyopathy, reproductive protection and so on .
    Phoenixin-14 TFA
  • HY-106688
    Alinidine

    St-567

    		 Potassium Channel Cardiovascular Disease
    Alinidine (St-567) is a specific bradycardic agent. Alinidine reduces the slope of the diastolic depolarization in sinoatrial tissue and Purkinje fibers. Alinidine shows antiischemic and antiarrhythmic effects .
    Alinidine
  • HY-106458
    Niludipine

    Bay a 7168

    		 Calcium Channel Cardiovascular Disease
    Niludipine (Bay a 7168) is an orally active calcium channel blocker and vasodilator with antihypertensive effects. Niludipine can improve early fatal ventricular arrhythmias induced by acute myocardial ischemia in rats. Niludipine can reduce left ventricular systolic and diastolic loads during pacing-induced angina pectoris. Niludipine can be used in the research of cardiovascular diseases such as coronary heart disease and myocardial ischemia .
    Niludipine
  • HY-111259
    Ro 31-1118 free base

    		Endogenous Metabolite Cardiovascular Disease
    Ro 31-1118 Free base is a compound exhibiting weak antihypertensive activity in patients with mild hypertension. Ro 31-1118 Free base demonstrated a reduction in heart rates and blood pressure post-exercise at varying doses. Ro 31-1118 Free base exhibited linear pharmacokinetics within the 10-80 mg dose range. Ro 31-1118 Free base showed no significant impact on diastolic blood pressure or adverse effects during the study.
    Ro 31-1118 free base
  • HY-103193R
    NKH477 (Standard)

    Colforsin dapropate hydrochloride (Standard)

    		 Reference Standards Adenylate Cyclase Cardiovascular Disease
    NKH477 (Standard) is the analytical standard of NKH477 (HY-103193). This product is intended for research and analytical applications. NKH477 (Colforsin dapropate hydrochloride) directly activates the catalytic unit of adenylate cyclase and increases intracellular cAMP. NKH477 is a forskolin derivative that improves cardiac failure mainly through its beneficial effects on diastolic cardiac function. NKH477 exerts an antiproliferative effect in vivo with an altered cytokine profile to inhibit the acute rejection of rat orthotopic lung allografts .
    NKH477 (Standard)
  • HY-160475
    AD-9308

    		Aldehyde Dehydrogenase (ALDH) Apoptosis Autophagy Cardiovascular Disease Metabolic Disease
    AD-9308 is a highly selective and orally active ALDH2 activator. AD-9308 activates ALDH2 to promote the clearance of 4-HNE, inhibiting myocardial fibrosis, inflammation and cell apoptosis. AD-9308 improves mitochondrial function, sarcoplasmic reticulum/ endoplasmic reticulum calcium transport and regulates autophagy, restoring intracellular homeostasis. AD-9308 improves the diastolic and systolic function of the heart in diabetic mice and reverses ventricular mal-reconstruction. AD-9308 can be used for the study of diabetic cardiomyopathy .
    AD-9308
  • HY-W343043
    Pyrazinoylguanidine

    PZG

    		 Drug Derivative Cardiovascular Disease Metabolic Disease
    Pyrazinoylguanidine (PZG) is an analogue of the potassium sparing diuretic, Amiloride (HY-B0285). Pyrazinoylguanidine can lower the systolic and diastolic blood pressure of patients with primary hypertension, has a certain effect on reducing heart rate, and does not affect the concentrations of electrolytes such as sodium, potassium, and chloride in the blood serum. Pyrazinoylguanidine can reduce the hyperglycemia and hyperinsulinemia in type 2 diabetes, reduce the levels of triglycerides, cholesterol, and free fatty acids, and reverse the hyperglycemia and hyperlipidemia induced by thiazide diuretics, such as Hydrochlorothiazide (HY-B0252). Pyrazinoylguanidine ican nhibit the reabsorption of urea by the renal tubules, thereby increasing the clearance rate and excretion volume of urea, reducing the serum urea concentration, and minimizing its toxic accumulation .
    Pyrazinoylguanidine

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: